Guided Therapeutics (GTHP) Equity Average (2016 - 2025)
Guided Therapeutics' Equity Average history spans 14 years, with the latest figure at -$5.8 million for Q4 2025.
- On a quarterly basis, Equity Average fell 19.3% to -$5.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.8 million, a 19.3% decrease, with the full-year FY2025 number at -$5.4 million, down 25.23% from a year prior.
- Equity Average hit -$5.8 million in Q4 2025 for Guided Therapeutics, down from -$5.6 million in the prior quarter.
- Over the last five years, Equity Average for GTHP hit a ceiling of -$2.8 million in Q4 2022 and a floor of -$9.4 million in Q1 2021.
- Historically, Equity Average has averaged -$5.1 million across 5 years, with a median of -$4.9 million in 2024.
- Biggest five-year swings in Equity Average: surged 58.05% in 2022 and later plummeted 40.66% in 2024.
- Tracing GTHP's Equity Average over 5 years: stood at -$6.6 million in 2021, then surged by 58.05% to -$2.8 million in 2022, then crashed by 34.73% to -$3.7 million in 2023, then plummeted by 31.53% to -$4.9 million in 2024, then fell by 19.3% to -$5.8 million in 2025.
- Business Quant data shows Equity Average for GTHP at -$5.8 million in Q4 2025, -$5.6 million in Q3 2025, and -$5.2 million in Q2 2025.